ACTRN12611000060943已完成未知
A 12-week, randomised, double-blind, placebo controlled study of the sustained effects of ResvidaTM on circulatory function and cognition in obese adults
Professor Peter Howe0 个研究点目标入组 30 人开始时间: 2011年1月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Men or post-menopausal women (self reported cessation of menses for at least 12 months)
- •Age: 40-70 years.
- •Obese (BMI 30-45 kg/m2) but otherwise healthy
排除标准
- •- Supine BP above SBP 160 mmHg or DBP 100 mmHg
- •- Having cardiovascular disease, renal disease or diabetes
- •- Taking BP lowering medication
- •- Having any other medical condition or treatments (including supplements) which, in the opinion of the investigators, may influence the outcome of the study
- •- Smokers or those using nicotine replacement therapy
- •- Those unwilling to restrict food items containing high amounts of polyphenols (grape, grape juice, wine, peanuts, peanut butter, mulberries, green tea, soy and soy products)
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1 Level: LLT Classification code 10063582 Term: Constipation chronic System Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-GBShire-Movetis NV374
进行中（未招募）
1 期
A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipatioChronic constipationEUCTR2009-015719-42-FRMovetis NV374
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1Level: LLTClassification code 10063582Term: Constipation chronicSystem Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-BGShire-Movetis NV348
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioChronic constipationEUCTR2009-015719-42-CZShire-Movetis NV348
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1Level: LLTClassification code 10063582Term: Constipation chronicSystem Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-DKShire-Movetis NV348